Clovis Oncology | CLVS - Debt

Clovis Oncology reported $660.38M in Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Debt Change
Acorda Therapeutics ACOR:US USD 167.03M 20.66M
Agenus AGEN:US USD 13.16M 299K
AstraZeneca AZN:LN USD 29.23B 67M
Astrazeneca AZN:US USD 29.23B 67M
Clovis Oncology CLVS:US USD 660.38M 13.49M
Enanta Pharmaceuticals ENTA:US USD 1.42M 0
Esperion Therapeutics ESPR:US USD 259.9M 412K
GlaxoSmithKline GSK:LN GBP 20.99B 1.13B
Halozyme Therapeutics HALO:US USD 1.51B 1.63M
Heron Therapeutics HRTX:US USD 149.23M 52K
Insmed INSM:US USD 1.16B 348.29M
Intrexon XON:US USD 43.22M 38.85M
Ligand Pharmaceuticals LGND:US USD 76.74M 92K
Neurocrine Biosciences NBIX:US USD 169.4M 200K
Novartis NOVN:VX USD 27.91B 530M
Puma Biotechnology PBYI:US USD 98.31M 313K
Rigel Pharmaceuticals RIGL:US USD 39.45M 20K
Veracyte VCYT:US USD 400K 1.29M
YTE INCY:US USD 33.26M 326K